Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efavaleukin Alfa in Active SLE
NCT04680637Phase 2Terminated
- Sponsor
- Amgen
- Start
- May 2021
- Primary completion
- May 2023
- Modality
- Cytokines & Interferons, Fc-Fusion Proteins
- Countries
- 19
01
Overview
A Phase 2 trial of efavaleukin alfa in systemic lupus erythematosus (SLE), sponsored by Amgen. Started May 2021; status: terminated.
02
Drugs
efavaleukin alfa
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT04680637.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04680637.